Glycogen synthase kinase 3: more than a namesake

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Glycogen synthase kinase 3 (GSK3) is a multi-functional kinase regulating diverse physiological processes including metabolism, cell cycle, and neuroprotection.
• GSK3's substrates include glycogen synthase, tau protein, and beta-catenin, influencing pathways relevant to diseases like diabetes, cancer, and Alzheimer's.
• Elevated GSK3 activity is observed in type II diabetes and obesity, suggesting its role in glucose homeostasis disruption.

Purpose of the Study:

• To review recent advances in targeting GSK3 as a therapeutic strategy for diabetes.
• To discuss the challenges associated with developing selective GSK3 inhibitors for anti-diabetic applications.
• To address concerns regarding potential side effects, such as oncogene up-regulation, from GSK3 inhibition.

Main Methods:

• Literature review of recent studies on GSK3 function and inhibition.
• Analysis of research on GSK3's role in insulin signaling and glucose metabolism.
• Examination of preclinical and in vitro data on GSK3 inhibitors for anti-diabetic effects.

Main Results:

• GSK3 negatively regulates insulin-mediated glycogen synthesis and glucose homeostasis.
• GSK3 inhibitors have demonstrated in vitro and in vivo anti-diabetic effects.
• Achieving selectivity for GSK3 inhibition is challenging due to its multiple substrates and pathways, potentially leading to toxicity.

Conclusions:

• GSK3 represents a promising therapeutic target for type II diabetes due to its role in glucose metabolism.
• Developing selective GSK3 inhibitors is critical to maximize anti-diabetic benefits while minimizing risks of side effects and oncogenesis.
• Further research is needed to overcome selectivity challenges and ensure the safety and efficacy of GSK3-targeted anti-diabetic therapies.